assembly Bill A6493

2019-2020 Legislative Session

Establishes the sickle cell treatment act of 2019; appropriation

download bill text pdf

Sponsored By

Archive: Last Bill Status - In Assembly Committee


  • Introduced
  • In Committee
  • On Floor Calendar
    • Passed Senate
    • Passed Assembly
  • Delivered to Governor
  • Signed/Vetoed by Governor

Your Voice

do you support this bill?

Please enter your contact information

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.

Actions

view actions (2)
Assembly Actions - Lowercase
Senate Actions - UPPERCASE
Jan 08, 2020 referred to health
Mar 08, 2019 referred to health

Co-Sponsors

view additional co-sponsors

Multi-Sponsors

A6493 (ACTIVE) - Details

See Senate Version of this Bill:
S2281
Current Committee:
Assembly Health
Law Section:
Appropriations
Laws Affected:
Amd §365, Soc Serv L; add Art 31 Title 4 §3126, Pub Health L
Versions Introduced in Other Legislative Sessions:
2013-2014: S6239
2015-2016: S3256
2017-2018: A5313, S4054

A6493 (ACTIVE) - Summary

Furnishes preventive medicine to those with sickle cell, establishes prevention and treatment of sickle cell disease demonstration programs, and makes an appropriation thereto.

A6493 (ACTIVE) - Bill Text download pdf


                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                  6493

                       2019-2020 Regular Sessions

                          I N  A S S E M B L Y

                              March 8, 2019
                               ___________

Introduced  by  M.  of  A.  HYNDMAN,  JEAN-PIERRE, BLAKE, BARRON, PERRY,
  WRIGHT, JOYNER, TAYLOR, PICHARDO,  DICKENS,  BICHOTTE,  MOSLEY,  NIOU,
  DAVILA, PEOPLES-STOKES, DE LA ROSA, BARNWELL, RA, GALEF -- Multi-Spon-
  sored  by  --  M. of A. COOK, PRETLOW, SIMON, SIMOTAS -- read once and
  referred to the Committee on Health

AN ACT to amend the social services law and the public  health  law,  in
  relation  to  establishing  the sickle cell treatment act of 2019; and
  making an appropriation therefor

  THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section  1.  This  act  shall be known and may be cited as the "Sickle
Cell Treatment Act of 2019".
  § 2. Legislative findings. The legislature hereby finds  and  declares
the following:
  (1)  Sickle  cell  disease  (SCD) is an inherited disease of red blood
cells and the CDC (Centers for Disease Control) states  that  SCD  is  a
major  public  health  concern.  Approximately 1,000 American babies are
born with the disease each year, while globally 500,000 babies are  born
annually with the disease.
  (2) Sickle cell disease affects approximately 100,000 Americans and is
most  common in African-Americans as well as those of Hispanic, Mediter-
ranean and Middle Eastern ancestry. Nationally, SCD occurs  in  approxi-
mately  1:500  African-Americans, 1:36,000 Hispanics and 1:80,000 Cauca-
sians. However, in NYS (New York State) SCD occurs in 1:230 live  births
to  non-Hispanic  black  mothers, 1:2,320 births to Hispanic mothers and
1:41,647 Caucasian mothers.
  (3) Approximately 10% of SCD patients reside in NYS. In  NYS,  1:1,146
live  births  have  sickle  cell  disease,  with  12% of NYS sickle cell
disease births in the Hispanic population. Higher birth  rates  for  SCD
occur  in mothers who were born outside of the US. In NYS, approximately
80% of sickle cell disease patients live in the NYC area.

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.